JULIET试验中接受替沙来仑赛治疗患者的神经毒性分级
该研究回顾性将CTCAE、mCRES和ASTCT三种量表应用于JULIET试验中接受替沙来仑赛治疗的复发/难治性弥漫大B细胞淋巴瘤患者的神经毒性数据,由4位专家独立分级。截至2017年12月,111例输注患者中,CTCAE判定50例(45%)有神经毒性,mCRES和ASTCT均判定19例(17%),mCRES/ASTCT将31例CTCAE判定的神经毒性事件降为0级。结论认为CTCAE v4.03不适用于CAR-T相关神经毒性分级,CRES和ASTCT量表评估更准确。
要点
- 111例输注替沙来仑赛患者中,CTCAE判定50例(45%)有神经毒性,mCRES和ASTCT均判定19例(17%)。
- mCRES/ASTCT标准将31例CTCAE判定的神经毒性事件降级为0级。
- CTCAE v4.03并非为CAR-T相关神经毒性设计,分级欠佳;CRES和ASTCT量表评估更准确。
核心结论
- CTCAE v4.03并非为CAR-T细胞治疗相关神经毒性设计,用于分级欠佳。
- CRES和ASTCT量表测量免疫效应细胞相关神经毒性综合征,能更准确评估CAR-T细胞治疗后的神经毒性。
研究设计与样本
- 回顾性分析JULIET试验(2期、单臂、多中心、全球关键性试验,NCT02445248)中接受替沙来仑赛治疗的复发/难治性弥漫大B细胞淋巴瘤患者的个体水平神经毒性数据。
- 由4位具有3种不同CD19靶向CAR构建体管理经验的医学专家,独立使用CTCAE、ASTCT和mCRES三种量表对同一组神经毒性数据进行回顾性分级。
主要发现
- 根据美国食品药品监督管理局对神经毒性的定义使用CTCAE,截至2017年9月,106例输注替沙来仑赛的患者中62例发生神经毒性。
- 截至2017年12月,111例输注替沙来仑赛的患者中,4位专家识别出50例(45%)按CTCAE有任何级别神经毒性,19例(17%)按mCRES,19例(17%)按ASTCT。
- 根据mCRES/ASTCT标准重新评估,将31例被CTCAE判定为神经毒性的事件降级为0级。
关键数值与推荐
- CTCAE判定任何级别神经毒性50/111例(45%),mCRES判定19/111例(17%),ASTCT判定19/111例(17%)。
- mCRES/ASTCT标准将31例CTCAE判定的神经毒性事件降为0级。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor-T (CAR-T) cell therapy achieves durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), but may be associated with neurological toxicity (NT). We retrospectively assessed differences and concordance among 3 available grading scales (the National Cancer Institute Common Terminology Criteria for Adverse Events v4.03 [CTCAE], modified CAR-T Related Encephalopathy Syndrome [mCRES], and American Society for Transplantation and Cellular Therapy [ASTCT] scales) applied to the same set of NT data from the JULIET (A Phase 2, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory DLBCL) trial. Individual patient-level NT data from the phase 2, single-group, global, pivotal JULIET trial (NCT02445248) were retrospectively and independently graded, using CTCAE, ASTCT, and mCRES, by 4 medical experts with experience managing patients with 3 different CD19-targeted CAR constructs. According to the US Food and Drug Administration definition of NT using CTCAE, 62 of 106 patients infused with tisagenlecleucel had NT as of September 2017. Among 111 patients infused with tisagenlecleucel (as of December 2017), the 4 experts identified 50 patients (45%) who had any-grade NT per CTCAE, 19 (17%) per mCRES, and 19 (17%) per ASTCT. Reevaluation according to the mCRES/ASTCT criteria downgraded 31 events deemed NT by CTCAE to grade 0. This is the first study to retrospectively apply CTCAE, mCRES, and ASTCT criteria to the same patient data set. We conclude that CTCAE v4.03 was not designed for, and is suboptimal for, grading CAR-T cell therapy-associated NT. The CRES and ASTCT scales, which measure immune effector cell-associated neurotoxicity syndrome, offer more accurate assessments of NT after CAR-T cell therapy.
引用
- Maziarz RT, Schuster SJ, Romanov VV, et al. Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020. PMID: 32271898. doi:10.1182/bloodadvances.2019001305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。